The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

BACKGROUND: The AcSé-crizotinib program provides extensive screening of crizotinib-targeted genomic alteration in several malignancies. We here report the results in patients with esogastric MET-amplified adenocarcinomas. OBJECTIVE: The objective of the study was to evaluate the efficacy and tolerab...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Target Oncol
Autori principali: Aparicio, Thomas, Cozic, Nathalie, de la Fouchardière, Christelle, Meriaux, Emeline, Plaza, Jérome, Mineur, Laurent, Guimbaud, Rosine, Samalin, Emmanuelle, Mary, Florence, Lecomte, Thierry, Gomez-Roca, Carlos, Haineaux, Paul-Arthur, Gratet, Alain, Selves, Jannick, Menu, Yves, Colignon, Nikias, Johnson, Laetitia, Legrand, Frédéric, Vassal, Gilles
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2021
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8105218/
https://ncbi.nlm.nih.gov/pubmed/33847874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-021-00811-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi